1.50
2.04%
0.03
Vorhandelsmarkt:
1.49
-0.01
-0.67%
Schlusskurs vom Vortag:
$1.47
Offen:
$1.48
24-Stunden-Volumen:
2.37M
Relative Volume:
0.62
Marktkapitalisierung:
$1.01B
Einnahmen:
$711.41M
Nettoeinkommen (Verlust:
$-133.73M
KGV:
-7.8947
EPS:
-0.19
Netto-Cashflow:
$-199.99M
1W Leistung:
+1.35%
1M Leistung:
-2.60%
6M Leistung:
+0.67%
1J Leistung:
+50.45%
Opko Health Inc Stock (OPK) Company Profile
Firmenname
Opko Health Inc
Sektor
Branche
Telefon
305-575-4181
Adresse
4400 BISCAYNE BLVD., MIAMI, FL
Vergleichen Sie OPK mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.50 | 1.01B | 711.41M | -133.73M | -199.99M | -0.19 |
TMO
Thermo Fisher Scientific Inc
|
573.06 | 219.20B | 42.37B | 6.14B | 7.78B | 15.95 |
DHR
Danaher Corp
|
244.11 | 176.31B | 23.74B | 3.89B | 4.98B | 5.24 |
A
Agilent Technologies Inc
|
152.57 | 43.57B | 6.51B | 1.29B | 1.37B | 4.42 |
IQV
Iqvia Holdings Inc
|
205.69 | 37.33B | 15.32B | 1.41B | 1.96B | 7.62 |
IDXX
Idexx Laboratories Inc
|
427.33 | 34.99B | 3.84B | 866.24M | 792.60M | 10.37 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-06-29 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
2022-12-15 | Eingeleitet | H.C. Wainwright | Buy |
2022-01-24 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
2021-06-21 | Eingeleitet | Ladenburg Thalmann | Buy |
2019-11-25 | Eingeleitet | Piper Jaffray | Overweight |
2018-03-02 | Herabstufung | JP Morgan | Neutral → Underweight |
2017-09-14 | Herabstufung | JP Morgan | Overweight → Neutral |
2016-06-21 | Bestätigt | Standpoint Research | Buy |
2016-06-03 | Eingeleitet | Standpoint Research | Buy |
2016-03-31 | Bestätigt | Barrington Research | Outperform |
2015-10-16 | Eingeleitet | JP Morgan | Overweight |
2015-09-11 | Herabstufung | Jefferies | Buy → Hold |
2015-03-03 | Herabstufung | Oppenheimer | Outperform → Perform |
2014-05-12 | Bestätigt | Oppenheimer | Outperform |
2014-03-14 | Eingeleitet | Oppenheimer | Outperform |
2013-11-13 | Bestätigt | Ladenburg Thalmann | Buy |
2013-05-30 | Bestätigt | Ladenburg Thalmann | Buy |
2012-10-22 | Eingeleitet | Barrington Research | Outperform |
2011-12-01 | Bestätigt | Ladenburg Thalmann | Buy |
2011-07-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Opko Health Inc Aktie (OPK) Neueste Nachrichten
OPKO Health, Inc. (OPK) Stock: An Under $5 Gem with Biggest Upside Potential - Yahoo Finance
12 Stocks Under $5 With Biggest Upside Potential - Insider Monkey
Here's Why You Should Retain OPKO Health Stock in Your Portfolio - MSN
Opko health CEO Phillip Frost buys $220,425 in common stock - MSN
OPKO Health : Immediate Report -January 18, 2025 at 06:29 am EST - Marketscreener.com
BioReference faces $704,349 fine for medically unnecessary blood tests - MSN
Opko health CEO Phillip Frost buys $220,425 in common stock By Investing.com - Investing.com Australia
Phillip Md Et Al Frost Purchases 150,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock - MarketBeat
BioReference Health and OPKO Health Agree to Pay $704,349 to Settle Allegations that they Billed the - U.S. Politics Today
BioReference Health, OPKO Health Settle False Claims Violations - Bloomberg Law
Barclays PLC Acquires 329,870 Shares of OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Opko health CEO Phillip Frost buys $740,850 in stock By Investing.com - Investing.com Canada
Opko health CEO Phillip Frost buys $740,850 in stock - Investing.com India
OPKO Health, Inc. (NASDAQ:OPK) CEO Buys $740,000.00 in Stock - MarketBeat
Opko Health Engages Investors at J.P. Morgan Conference - TipRanks
OPKO Health (NASDAQ:OPK) Stock Rating Lowered by StockNews.com - MarketBeat
OPKO Health Announces Progress in EBV Vaccine Study, Stock Gains - MSN
OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Could Signal Some Risk - Simply Wall St
OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Opko Health stock buy rating reaffirmed, steady target on clinical trial - Investing.com Canada
OPKO Health's (OPK) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
OPKO Health (NASDAQ:OPK) Upgraded by StockNews.com to "Hold" Rating - MarketBeat
OPKO Health’s ModeX Therapeutics Announces Epstein-Barr - GlobeNewswire
OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck - Yahoo Finance
OPKO Health (NASDAQ:OPK) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) Stake Cut by Geode Capital Management LLC - MarketBeat
3 Stocks That Wall Street Insiders Can't Stop Buying - MSN
3 Stocks That Wall Street Insiders Can’t Stop Buying - sharewise
Opko Health Inc (OPK-Q) QuotePress Release - The Globe and Mail
OPKO Health, Inc. (NASDAQ:OPK) Short Interest Down 14.0% in December - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) Shares Sold by State Street Corp - MarketBeat
OPKO Health (NASDAQ:OPK) Downgraded to Sell Rating by StockNews.com - MarketBeat
OPKO Health delivers 57% gain after January Fair Value signal flags undervaluation - Investing.com Canada
Esoteric Testing Market is Set to Experience a Revolutionary Growth | Labcorp, Quest Diagnostics, OPKO Health - openPR
Connected Drug Delivery Devices Market is Dazzling Worldwide - openPR
OPKO Health (NASDAQ:OPK) Raised to Hold at StockNews.com - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) CEO Buys $198,750.00 in Stock - MarketBeat
Phillip Frost Buys Handful Of Shares In OPKO Health - Simply Wall St
Opko health CEO Phillip Frost buys $199,375 in stock By Investing.com - Investing.com South Africa
Opko health CEO Phillip Frost buys $199,375 in stock - Investing.com
Opko Health stock hits 52-week high of $1.75 amid growth - Investing.com Canada
Finanzdaten der Opko Health Inc-Aktie (OPK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Opko Health Inc-Aktie (OPK) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 15 '25 |
Buy |
1.48 |
500,000 |
740,850 |
213,036,477 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 13 '24 |
Buy |
1.59 |
125,000 |
199,375 |
212,536,477 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 11 '24 |
Buy |
1.56 |
500,000 |
781,050 |
212,411,477 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 29 '24 |
Buy |
1.53 |
199,072 |
305,376 |
211,911,477 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 22 '24 |
Buy |
1.59 |
100,000 |
159,000 |
211,712,405 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 14 '24 |
Buy |
1.62 |
100,000 |
161,980 |
211,612,405 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 08 '24 |
Buy |
1.50 |
280,183 |
421,535 |
211,512,405 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):